Review discusses cancer vaccines for head and neck cancer

This narrative review examines the potential role of therapeutic cancer vaccines in treating head and neck squamous cell carcinoma. The article discusses personalized cancer vaccines and the combination of immune checkpoint inhibitor therapy with these vaccines. The study does not report a specific sample size or follow-up period because it is a review of existing information rather than a new clinical trial. No adverse events, serious adverse events, or discontinuations were reported in this text because the source did not provide safety data. Readers should understand that this is a narrative review, meaning it summarizes other studies rather than presenting new patient data. The main reason to be careful is that the evidence comes from a review without a defined primary outcome or specific population numbers. Readers should take from this that these approaches are being explored, but more research is needed to confirm their effectiveness and safety in this specific cancer type.